Last updated: July 31, 2026
Astepro Allergy is Bayer’s U.S. over-the-counter azelastine hydrochloride nasal spray for temporary relief of nasal congestion, sneezing, runny nose and itchy nose caused by seasonal or perennial allergic rhinitis. The product contains azelastine hydrochloride 0.1%, equivalent to 137 micrograms of azelastine per spray, and is marketed as a 24-hour, once-daily nasal antihistamine.[1]
The product’s primary growth phase was the 2021 FDA switch from prescription to OTC status. No major late-stage development program is associated with Astepro Allergy. Commercial performance depends on OTC allergy-season demand, retail distribution, brand advertising, pricing and competition from Flonase, Nasacort, Claritin, Zyrtec and store-brand nasal sprays.
What is Astepro Allergy and how does it work?
Astepro Allergy is a nasal spray containing azelastine hydrochloride, a topical H1-histamine receptor antagonist. It also has anti-inflammatory activity relevant to allergic rhinitis.
| Product characteristic |
Astepro Allergy |
| Active ingredient |
Azelastine hydrochloride |
| Strength |
0.1% |
| Dose |
1 or 2 sprays per nostril, depending on labeling and age |
| Route |
Intranasal |
| FDA status |
OTC |
| Primary indication |
Temporary relief of seasonal allergy symptoms |
| Manufacturer and marketer |
Bayer Consumer Health in the United States |
| Prescription predecessor |
Astepro nasal spray |
| Dosage form |
Metered-dose nasal spray |
| Primary competitive class |
Intranasal antihistamines |
Astepro Allergy differs from intranasal corticosteroids such as fluticasone and triamcinolone. Intranasal antihistamines can provide relatively rapid symptom relief, while corticosteroids generally have a broader anti-inflammatory role and are often positioned for persistent nasal inflammation.
What is the FDA regulatory status of Astepro Allergy?
The FDA approved the Astepro Allergy OTC switch in 2021. The switch made azelastine hydrochloride 0.1% nasal spray available without a prescription for consumers age six and older, subject to the OTC Drug Facts labeling.[2]
The prescription product had been available before the switch. Bayer launched Astepro Allergy in the United States in June 2021 and positioned it as the first 24-hour, over-the-counter nasal antihistamine spray in the U.S. market.[3]
FDA milestones
| Date |
Regulatory event |
| 1996 |
Azelastine nasal spray approved in the United States as a prescription product |
| 2021 |
FDA approved the prescription-to-OTC switch for Astepro Allergy |
| June 2021 |
Bayer launched Astepro Allergy nationally |
| 2022 onward |
Product remained in the OTC allergy category, with commercial expansion through retail and e-commerce channels |
The product is regulated as an OTC drug under an approved NDA and its authorized labeling. It is not a biologic and does not face biosimilar substitution risk.
What clinical trials support Astepro Allergy?
Astepro Allergy does not have a current registrational clinical-trial program comparable to a new prescription medicine. Its evidence base consists primarily of earlier azelastine clinical trials and FDA studies supporting OTC consumer use.
The OTC switch required evidence that consumers could:
- Understand the label.
- Correctly identify whether the product was appropriate for their symptoms.
- Select the product without a healthcare professional.
- Use the nasal spray according to the proposed directions.
- Recognize situations requiring medical attention.
The established prescription development program evaluated azelastine for seasonal allergic rhinitis and perennial allergic rhinitis. Studies generally assessed changes in sneezing, nasal itching, rhinorrhea and congestion compared with placebo or active treatment.
Current clinical-development assessment
| Development area |
Status |
| New molecular entity trials |
None |
| Phase 3 registration program |
Completed historically |
| OTC label-comprehension studies |
Used for the 2021 switch |
| Pediatric OTC use |
Included in FDA labeling for eligible ages |
| New indication development |
No major public program identified |
| Combination-product development |
No major Astepro Allergy program identified |
| Biosimilar development |
Not applicable |
ClinicalTrials.gov is not the principal source of commercial or regulatory exclusivity information for this product. The relevant regulatory event was the FDA OTC switch rather than a new therapeutic indication.[4]
When did Astepro Allergy lose prescription exclusivity?
Astepro Allergy’s commercial transition was driven by OTC approval rather than a conventional generic-entry event. Prescription azelastine nasal spray has been marketed for decades, and the active ingredient is off-patent in the conventional small-molecule sense.
The important distinction is between:
- The active ingredient, azelastine hydrochloride.
- The prescription product’s formulation and labeling.
- The OTC product’s brand, packaging and consumer positioning.
- Any remaining formulation, device or manufacturing rights.
The 2021 OTC switch expanded the addressable consumer market but did not create a new long-duration patent estate comparable to a recently approved innovative medicine.
What patents protect Astepro Allergy?
The principal commercial protection for Astepro Allergy is brand equity, FDA-approved labeling, packaging, distribution and retail execution rather than a clearly dominant composition-of-matter patent.
| Protection category |
Relevance to Astepro Allergy |
| Composition-of-matter patent |
Limited or expired for the established active ingredient |
| Formulation patent |
Potentially relevant to specific concentration, excipients or spray characteristics |
| Device patent |
Potentially relevant to metered-dose delivery components |
| Method-of-use patent |
Limited for established allergic-rhinitis use |
| Trademark protection |
Important for the Astepro and Astepro Allergy brands |
| FDA regulatory protection |
OTC labeling and approved application status |
| Manufacturing know-how |
Relevant to spray uniformity, stability and filling operations |
| Retail exclusivity |
Commercial rather than statutory |
A definitive patent-risk assessment requires a current search of FDA Orange Book listings, USPTO records, assignment records, and litigation databases. The Orange Book is more relevant to prescription Astepro than to the OTC consumer presentation. OTC products generally do not receive the same Orange Book patent-listing treatment as prescription products.
Does Astepro Allergy face Paragraph IV challenges?
Astepro Allergy is not currently exposed to the standard Paragraph IV pathway in the same way as a branded prescription drug with an active Orange Book listing. A generic manufacturer can pursue an abbreviated pathway for prescription azelastine products, but an OTC competitor may instead rely on a different regulatory route, including an OTC monograph pathway or an approved application.
The main competitive risks are therefore:
- Store-brand azelastine nasal sprays.
- Prescription-to-OTC or authorized-generic competition.
- Private-label products sold through pharmacies and mass retailers.
- Alternative antihistamine sprays.
- Intranasal corticosteroids.
- Oral antihistamines.
- Combination nasal products.
No major public Paragraph IV litigation has been associated with the current Astepro Allergy OTC brand based on the publicly established regulatory record through mid-2024.
What formulations are protected by Astepro Allergy?
The commercial product is a metered nasal spray containing 0.1% azelastine hydrochloride. Product differentiation can arise from the following technical characteristics:
- Spray volume and dose uniformity.
- Pump performance.
- Droplet and plume properties.
- Preservative system.
- Container-closure compatibility.
- Chemical stability.
- Shelf life.
- User experience, including taste and post-nasal drip.
- Packaging designed for consumer self-selection.
These attributes can create manufacturing and quality-control barriers, but they do not necessarily prevent a competing manufacturer from developing an equivalent product.
A formulation competitor would need to demonstrate pharmaceutical quality, stability, delivered-dose uniformity and compliance with the applicable FDA pathway. The technical barrier is meaningful, but it is lower than the barrier associated with sterile injectable biologics or complex inhaled products.
How strong is the Astepro Allergy patent estate?
Astepro Allergy has a moderate-to-weak patent position when measured against innovative prescription products. Its commercial defensibility is stronger than its apparent molecule-level exclusivity because Bayer controls the brand, shelf placement and consumer marketing.
| Patent-estate factor |
Assessment |
| Active ingredient exclusivity |
Weak; mature small molecule |
| Core allergic-rhinitis indication |
Weak; established use |
| OTC regulatory position |
Moderate |
| Formulation and device barriers |
Moderate |
| Brand recognition |
Moderate to strong |
| Manufacturing complexity |
Moderate |
| Generic substitution risk |
Moderate to high |
| Biosimilar risk |
None |
The product’s economic life is likely to be determined by brand investment and category share rather than by patent expiration.
What is the competitive landscape for Astepro Allergy?
Astepro Allergy competes across several OTC categories.
| Competitor |
Active ingredient or class |
Competitive position |
| Flonase Allergy Relief |
Fluticasone propionate |
Major OTC nasal-steroid brand |
| Nasacort Allergy 24HR |
Triamcinolone acetonide |
Major OTC nasal-steroid brand |
| Rhinocort Allergy |
Budesonide |
OTC nasal corticosteroid |
| Claritin |
Loratadine |
Oral antihistamine |
| Zyrtec |
Cetirizine |
Oral antihistamine |
| Allegra |
Fexofenadine |
Oral antihistamine |
| Store-brand sprays |
Azelastine, fluticasone or other ingredients |
Price-driven competition |
| Dymista |
Azelastine plus fluticasone |
Prescription combination product |
Astepro’s principal differentiation is rapid topical antihistamine activity and once-daily dosing. Fluticasone products retain a strong position because consumers and clinicians associate nasal corticosteroids with broad allergy symptom control.
What is the Astepro Allergy market outlook?
Public companies generally do not report Astepro Allergy revenue as a separate line item. Bayer reports consumer-health performance at a broader category or regional level, which limits direct verification of product sales.
A practical market projection should therefore use category growth, distribution, price and share assumptions rather than a purported company-reported product forecast.
Scenario projection
The following directional scenario applies a base-year index of 100 to U.S. Astepro Allergy retail sales. It is a market model, not a reported Bayer forecast.
| Scenario |
Annual unit or sales trend |
2029 index |
Main assumptions |
| Downside |
-2% |
90 |
Heavy private-label erosion and weak advertising support |
| Base |
3% |
116 |
Stable allergy category, sustained distribution and modest price growth |
| Upside |
7% |
140 |
Strong seasonal demand, expanded household penetration and premium pricing |
The base case assumes continued OTC category demand but no new indication, no major formulation innovation and no material patent-driven price protection.
Revenue exposure
Astepro Allergy is strategically relevant to Bayer’s U.S. consumer-health portfolio, but it is unlikely to represent the same financial exposure as a large prescription drug. Revenue is concentrated in the spring and fall allergy seasons, with sensitivity to:
- Pollen intensity.
- Temperature and precipitation.
- Consumer health spending.
- Retailer inventory.
- Digital advertising.
- Shelf placement.
- Private-label pricing.
- Switching between nasal and oral therapies.
The 2021 OTC launch created the largest identifiable revenue expansion event. Future growth is more likely to come from market-share gains and repeat purchase than from regulatory exclusivity.
What generic-launch scenarios exist for Astepro Allergy?
Scenario 1: Prescription generic competition
Manufacturers can compete with prescription azelastine products through abbreviated approval pathways, subject to applicable FDA requirements. This competition affects the prescription channel more directly than the branded OTC product.
Scenario 2: OTC private-label azelastine
Retailers may seek store-brand azelastine products. Price competition would be strongest where consumers recognize the active ingredient and pharmacists recommend lower-cost alternatives.
Scenario 3: Brand-led defense
Bayer can defend share through advertising, retailer contracts, packaging changes, coupons and product-line extensions. These measures protect commercial share but do not create statutory exclusivity.
Scenario 4: Formulation or combination competition
Combination sprays containing an antihistamine and corticosteroid could capture consumers seeking broader symptom control. This risk is more clinically differentiated than simple price competition.
What litigation and licensing deals affect Astepro Allergy?
No major public patent settlement or active branded-product litigation is central to Astepro Allergy’s current commercial outlook. The product’s historical development and commercialization involved corporate ownership changes associated with the broader azelastine franchise, including Meda and Mylan/Viatris, before Bayer’s consumer-health commercialization of Astepro Allergy in the United States.[3]
The key transaction was Bayer’s acquisition of U.S. OTC rights and its subsequent launch strategy, rather than a publicly disclosed late-stage licensing deal tied to a new formulation.
How does Astepro Allergy compare with Flonase Allergy Relief?
| Attribute |
Astepro Allergy |
Flonase Allergy Relief |
| Drug class |
Nasal antihistamine |
Nasal corticosteroid |
| Active ingredient |
Azelastine |
Fluticasone propionate |
| Consumer positioning |
Fast allergy symptom relief |
Broad allergy control |
| Dosing |
Once daily under labeling |
Once daily under labeling |
| Main risk |
Price and private-label substitution |
Mature category competition |
| Patent dependence |
Low |
Low at the OTC brand level |
| Key differentiation |
Antihistamine mechanism and rapid onset |
Established corticosteroid efficacy and brand scale |
Astepro is best positioned where consumers prioritize rapid relief and prefer a nasal antihistamine. Flonase has broader recognition in the OTC nasal-allergy segment and competes heavily for shelf space and advertising share.
Key Takeaways
- Astepro Allergy is an OTC azelastine hydrochloride 0.1% nasal spray marketed by Bayer in the United States.
- The FDA approved its prescription-to-OTC switch in 2021.
- No major ongoing late-stage clinical-trial program is associated with the product.
- The active ingredient and core indication are mature, limiting molecule-level patent protection.
- Formulation, spray-device, manufacturing and trademark rights provide commercial protection but are not equivalent to strong composition-of-matter exclusivity.
- Paragraph IV exposure is less central because the current product is OTC.
- The largest risks are private-label azelastine, prescription generics, intranasal corticosteroids and combination sprays.
- A reasonable directional U.S. base case is low-single-digit annual sales growth through 2029, driven by OTC distribution and allergy-season demand rather than new regulatory exclusivity.
- Biosimilar risk does not apply because Astepro Allergy is a small-molecule nasal spray.
FAQs
Is Astepro Allergy still available without a prescription?
Yes. Astepro Allergy is marketed in the United States as an OTC azelastine hydrochloride nasal spray for eligible consumers.
Is Astepro Allergy the same as prescription Astepro?
Both products contain azelastine hydrochloride, but prescription and OTC presentations can differ in labeling, packaging, strength options and approved directions.
Can a generic manufacturer copy Astepro Allergy?
A manufacturer may develop a competing azelastine nasal spray, but the regulatory route depends on the specific product, strength, labeling and intended market channel.
Does Astepro Allergy have biosimilar competition?
No. Biosimilars apply to biological products. Astepro Allergy contains the small-molecule drug azelastine hydrochloride.
What is the main commercial threat to Astepro Allergy?
The main threat is substitution by lower-priced store-brand nasal sprays and established OTC nasal corticosteroid brands, particularly Flonase and Nasacort.
References
-
U.S. Food and Drug Administration. (2021). Astepro Allergy drug facts label and prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2021, June 17). FDA approves first over-the-counter nasal spray containing azelastine hydrochloride. FDA.
-
Bayer AG. (2021, June 15). Bayer launches Astepro Allergy, the first and only 24-hour steroid-free nasal spray available over the counter in the United States. Bayer investor and corporate communications.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov search results for azelastine hydrochloride nasal spray and allergic rhinitis. ClinicalTrials.gov.
